As of Wednesday close, Galera Therapeutics Inc.’s (NASDAQ:GRTX) stock was down -$0.02, moving down -7.31 percent to $0.19. The average number of shares traded per day over the past five days has been 9,153,561 shares. 3 times new highs have been achieved over the past 5 days, with a -$0.0083 fall in that time frame. In the last twenty days, the average volume was 3,344,315, while in the previous 50 days, it was 3,875,740.
Since last month, GRTX stock retreated -15.32%. Shares of the company fell to $0.1860 on 09/20/23, the lowest level in the past month. A 52-week high of $3.59 was reached on 06/13/23 after having rallying from a 52-week low of $0.19. Since the beginning of this year, GRTX’s stock price has dropped by -87.24% or -$1.2999, and marked a new high 15 times. However, the stock has declined by -94.70% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
GRTX stock investors should be aware that Galera Therapeutics Inc. (GRTX) stock had its last reported insider trading activity 189 days ago on Mar 16. Bachleda Mark, the Chief Commercial Officer of the company, purchased of 11,000 shares for $2.25 on Mar 16. It resulted in a $24,717 investment by the insider. Degnan Chris added 10,000 shares at an average price of $1.96 on Mar 13. The insider now owns 10,000 shares following the transaction. On Mar 10, President and CEO Sorensen Mel bought 100,000 shares at $1.68 apiece. The transaction was valued at $168,120.
Financial Health
In the three months ended June 29, Galera Therapeutics Inc.’s quick ratio stood at 3.10, while its current ratio was 3.10, showing that the company is able to pay off its debt. Based on annual data, GRTX earned $11.57 million in gross profit and brought in $51.23 million in revenue.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected Galera Therapeutics Inc. to report -$0.38 quarterly earnings, the actual figure was -$0.48 per share, beating the consensus estimate by -26.30%. During the quarter, the company generated -$16.8 million in EBITDA. The liabilities of Galera Therapeutics Inc. were 163.28 million at the end of its most recent quarter ended June 29, and its total debt was $149.58 million. The value of shareholders’ equity is $43.93 million.
Technical Picture
This quick technical analysis looks at Galera Therapeutics Inc.’s (GRTX) price momentum. With a historical volatility rate of 61.81%, the RSI 9-day stood at 20.34% on 20 September.
With respect to its five-day moving average, the current Galera Therapeutics Inc. price is down by -4.18% percent or -$0.0083. At present, GRTX shares trade -11.62% below its 20-day simple moving average and -92.91% percent below its 100-day simple moving average. However, the stock is currently trading approximately -93.38% below its SMA50 and -88.82% below its SMA200.
Stochastic coefficient K was 20.59% and Stochastic coefficient D was 16.70%, while ATR was 0.0314. Given the Stochastic reading of 8.54% for the 14-day period, the RSI (14) reading has been calculated as 18.46%.
Analyst Ratings
Galera Therapeutics Inc. downgraded its rating on Galera Therapeutics Inc. (NASDAQ: GRTX) to a Neutral in a note to investors on August 10, 2023. The analysts firm previously had an Overweight rating on the stock.Galera Therapeutics Inc. (GRTX) has been rated Hold by analysts. According to 0 brokerage firms, GRTX is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Galera Therapeutics Inc. stock as buy, with 0 recommending it as overweight.
With a median target price of $0.30, the current consensus forecast for the stock is $0.25 – $0.50. Based on these forecasts, analysts predict Galera Therapeutics Inc. (GRTX) will achieve an average price target of $0.35.
